Physician profile
John E Grubbs
NPI 1710077110
$11,666.55
in general payments reported to CMS, 2019-2025
54 companies · $58.04 in 2025
The $58.04 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,238 · 2020: $1,971 · 2021: $2,539 · 2022: $2,723 · 2023: $2,105 · 2024: $32.90 · 2025: $58.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $994.80 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $779.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $715.27 | 2019-2025 | |
| Emd Serono, INC. | $689.45 | 2019-2023 | Mavenclad |
| Neurelis, INC. | $592.43 | 2020-2023 | Valtoco |
| Supernus Pharmaceuticals, INC. | $572.73 | 2019-2022 | |
| Amgen INC. | $499.22 | 2019-2022 | |
| Lilly USA, LLC | $456.42 | 2019-2023 | Reyvow, Emgality, Amyvid |
| Biogen, INC. | $435.20 | 2019-2023 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $430.48 | 2019-2023 | Nuplazid |
| Csl Behring | $389.75 | 2019-2023 | Hizentra |
| Jazz Pharmaceuticals INC. | $383.54 | 2019-2023 | Epidiolex |
| Teva Pharmaceuticals USA, INC. | $381.42 | 2019-2023 | Austedo Xr, Austedo |
| Sk Life Science, INC. | $308.33 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $303.16 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Grubbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.